Our Blog
Follow:
4bases’ paper of the month – April 2021: Interindividual immunogenic variants: Susceptibility to coronavirus, respiratory syncytial virus and influenza virus
Our team’s reading recommendation for this month goes to “Interindividual immunogenic variants: Susceptibility to coronavirus, respiratory syncytial virus and influenza virus” by Farseh Darbeheshti et al. from Tehran University of Medical Sciences[1], an interesting...
4bases’ paper of the month – March 2021: Breast Cancer Risk Genes – Association Analysis in More than 113,000 Women
Our team’s reading recommendation for this month goes to “Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women” by Leila Dorling et al. from @University of Cambridge[i], an extremely interesting paper just published in @NEJM Group that reports on...
4bases’ paper of the month February 2021: Microbiome data enhances predictive models of lung function in people with cystic fibrosis
Our team’s reading recommendation for this month goes to “Microbiome data enhances predictive models of lung function in people with cystic fibrosis” by Conan Y Zhao et al. from @Georgia Tech[i], a very interesting paper just published in the journal of infectious...
4bases’ paper of the month: January 2021: a higher susceptibility to COVID-19 in the presence of specific alleles?
HLA involvement in COVID 19: new data from an Italian study suggest there might be a higher disease susceptibility in the presence of specific alleles. Our team’s reading recommendation for this month goes to “HLA allele frequencies and susceptibility to...
Studies on Breast and Ovarian Cancer performed with 4bases’ kits at University of Palermo
With our best wishes for a successful 2021 we'd like to share with you 2 papers recently published by the University of Palermo policlinico Giaccone. These 2 studies on #breastcancer and on #ovariancancer were performed with our #BRaCA (over a thousand patients) &...
4bases’ paper of the month – December 2020: “BRCA testing in a genomic diagnostics referral center during the COVID-19 pandemic”
Our team’s reading recommendation for this month goes to “BRCA testing in a genomic diagnostics referral center during the COVID-19 pandemic” by Minucci et al. [i], a very interesting paper with which the Molecular and Genomics Diagnostics Unit of...
Renewal of the ISO 13485 – 2016 certification for 4bases
The annual audit held during the second week of November has confirmed and renewed 4bases’ ISO 13485 certification, absolutely essential for the production and commercialization of CE-IVD medical devices. On top of this, 4bases quality assurance staff is working to...
4bases’ paper of the month – November 2020: “Gut microbiota and COVID-19 – possible links and implications”
Our team’s reading recommendation for this month goes to “Gut microbiota and COVID-19 – possible links and implications” by Dahr & Mohanty[i], a highly inspiring reflection on the potential role of the gut microbiota in the pathophysiology of COVID-19. The...
4bases’ paper of the month – October 2020: “Microbiome: Effects of Ageing and Diet”
Our team’s reading recommendation for this month goes to “Microbiome: Effects of Ageing and Diet” by Salazar& al[i], an excellent review and study on our current knowledge of the gut microbiome and how it is influenced by ageing and diet. The influence of the...
4bases’ paper of the month – September 2020: “Molecular profiling for precision cancer therapies”
Our team’s reading recommendation for this month goes to “Molecular profiling for precision cancer therapies” by Malone et al[i] This extremely interesting and complete paper reviews the different approaches to precision medicine in the field of oncology and...
Cancer prevention campaign
We at 4bases never forget that patients are for us the most important persons and that prevention is absolutely essential in our fight against cancer. It was therefore a must for us to support the European Code Against Cancer by reminding the 12 ways to reduce cancer risk as published by the International Agency for Research on Cancer at the WHO.
“Enabling Technologies for Personalized and Precision Medicine”
Reviewing a number of enabling technologies from bioengineering to artificial intelligence this month’s paper shows how much and how fast medicine is moving away from its old “one size fits all“ mentality toward personalized and precision medicine.
“Targeting DNA repair in cancer: current state and novel approaches” 4bases’ paper of the month
We always hear about the highly celebrated Precision Medicine, but what is this in reality? An answer might be “the possibility to adopt a very personalized way to exploit at best the existing and novel therapeutic options”. A practical example is provided by the...
ILC Group is the new exclusive distributor for 4bases in Portugal
4bases proudly announces a new important step in its development plan. Thanks to an exclusive commercial partnership with the ILC Group, 4bases' products and services are now available to more portuguese customers. All is being done through this new partnership for...
“Toward a more precise future for oncology”
There is no doubt that, as we’re moving toward a more precise future for oncology, the medical community will need precise answers to new molecular diagnostic questions. While only a minority of oncology patients currently benefit from genomic matching to...
4bases proudly announces a new partnership with MONACO FOUNDRY to accelerate its business development
Manno, March 31, 2020 4bases SA, a swiss-based company specialized in the development, production and commercialization of reagent kits for NGS (New Generation Sequencing) is delighted to announce its new partnership with MONACO FOUNDRY, a global leader in business...
New! Custom panel
Custom panel – developed on-demand for your specific RUO or CE-IVD specific applications.
New corporate brochure
To make your choice easier and faster 4bases' company and product information are gathered in the new brochure
4bases announces its new partnership with Saphetor SA
4bases announces its new partnership with Saphetor SA to accelerate data interpretation for targeted NGS panels. Manno, December 3st, 2019. 4bases SA, a Swiss-based company specialized in the development, production, and commercialization of reagent kits and gene...
A new step into precision medicine
Since the end of May 2019, around 40% of patients with HR+/HER2- breast cancer can count on a new drug developed by Novartis and approved by the FDA. This new development is another important step into the field of precision medicine. Piqray® is indeed specific to...
4bases launches a new website
After the renewal of our ISO13485:2016 certification in May, the entry of new products in our pipeline and the opening of new markets, the Swiss supplier of CE IVD certified genetic diagnostic tests 4bases launches today its new website. Concise but comprehensive, the...